Cancer Family
Epithelial Neoplasm
CI-CAN-00000016Explore in graph →
Non-malignant7,525 active trials118 approved drugs1,152 evidence items
- NCIt
- C3709
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000016Explore in graph →
Clinical trials
26,878 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06261190 | Active Surveillance for Low-risk Papillary Thyroid Carcinoma(MAeSTro-EXP) | enrolling by invitation | — | 499 | National Cancer Center, KoreaOTHER_GOV | 1 | May 11, 2025 | clinicaltrials |
| NCT06962449 | Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer(REALM-Post) | enrolling by invitation | — | 500 | Shanghai Chest Hospital |
| 1 |
| May 8, 2025 |
| clinicaltrials |
| NCT06963060 | Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)(GALENT-BT) | enrolling by invitation | Phase 2 | 44 | Wei GongOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT06958445 | Prevention of Oral Mucositis and Improvement of Quality of Life for Patients With Breast Cancer Undergoing Adjuvant Radiotherapy(SAFE) | enrolling by invitation | Phase 2 | 90 | Taipei City HospitalOTHER_GOV | 1 | May 6, 2025 | clinicaltrials |
| NCT06931808 | Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon Cancer | enrolling by invitation | Phase 4 | 20 | First Affiliated Hospital of Ningbo UniversityNETWORK | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06923020 | Association of Nutritional Status With Immune Checkpoint Inhibitor Efficacy in Metastatic Metastatic Esophagogastric Cancer. | enrolling by invitation | — | 200 | Yongxu JiaOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT06690216 | Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors(PD-L1-PET) | enrolling by invitation | Phase 1 / Phase 2 | 100 | Man HuOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06715501 | Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma | enrolling by invitation | N/A | 20 | First Affiliated Hospital of Ningbo UniversityNETWORK | 1 | Mar 25, 2025 | clinicaltrials |
| NCT04915495 | The Use of the LuViva Advanced Cervical Scan to Identify Women at High-Risk for Cervical Neoplasia | enrolling by invitation | N/A | 400 | Guided TherapeuticsINDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06883136 | Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly Patients | enrolling by invitation | — | 43 | Qianfoshan HospitalOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06876675 | LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer | enrolling by invitation | — | 167 | Peking University Third HospitalOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06863831 | A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC | enrolling by invitation | N/A | 536 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06852144 | PET-TC in Thyroid Evaluation(PEPATI-MN-2024) | enrolling by invitation | — | 418 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06846736 | ALK Digital Pathology Outcome Predition, Multi Institutional, Restrospective Study(ALKDigPath) | enrolling by invitation | — | 200 | Sheba Medical CenterOTHER_GOV | 1 | Feb 26, 2025 | clinicaltrials |
| NCT06405295 | Intensive Adjuvant Therapy for TNBC with BRCA Gene Mutation | enrolling by invitation | — | 600 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06821490 | Validation of TAD in HER-2 with More Than 2 Lymph Nodes(DAD-HER2) | enrolling by invitation | — | 21 | Fundación para la Investigación del Hospital Clínico de ValenciaOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT01868490 | The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells | enrolling by invitation | Phase 1 / Phase 2 | 20 | Siriraj HospitalOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06816966 | Chemotherapy-immunotherapy-based Split-course Adaptive Hypofractionated Radiotherapy for Extensive-stage SCLC(CISART) | enrolling by invitation | Phase 2 | 35 | Fujian Medical University Union HospitalOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06774170 | Structured Follow-up Intervention on Glucose Status After Pancreatic Cancer Surgery(FiGluR) | enrolling by invitation | N/A | 40 | Dokuz Eylul UniversityOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06773156 | Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer | enrolling by invitation | Phase 2 | 37 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT04755517 | Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women (HPV400)(HPV400) | enrolling by invitation | N/A | 14,000 | Tampere University HospitalOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06763640 | Prognostic Value of TIL in Nasopharyngeal Carcinoma | enrolling by invitation | — | 216 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06759857 | FHND9041 Versus Afatinib for Non-small Cell Lung Cancer(FHND9041) | enrolling by invitation | Phase 3 | 350 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06747832 | INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer(iNK-SCLC) | enrolling by invitation | Early Phase 1 | 10 | Guangzhou Ruixin Biotechnological Co., LTDINDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06647836 | The Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma | enrolling by invitation | — | 1,000 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06730477 | Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma | enrolling by invitation | — | 500 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06712017 | Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China | enrolling by invitation | — | 100 | GrandPharma (China) Co., Ltd.INDUSTRY | 1 | Dec 5, 2024 | clinicaltrials |
| NCT05212103 | PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9(CANSI) | enrolling by invitation | — | 30 | Turku University HospitalOTHER_GOV | 1 | Dec 4, 2024 | clinicaltrials |
| NCT06705049 | Retrospective Study on Leptomeningeal Metastasis of Solid Tumors | enrolling by invitation | — | 107 | Shanghai Zhongshan HospitalOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT05376553 | Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck | enrolling by invitation | Phase 1 | 24 | Krzysztof MisiukiewiczOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06610240 | Perioperative Treatment Outcomes of Early NSCLC(Peri-R) | enrolling by invitation | — | 500 | Shanghai Chest HospitalOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT06583395 | Quest to Analyze One Thousand Humans Meditating(QUANTUM) | enrolling by invitation | — | 3,000 | Tobias Moeller-BertramINDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT06646263 | Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic Studies | enrolling by invitation | — | 150 | Institute of Applied BiosciencesOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06647264 | A Multicenter Prospective Observational Study of Computer-aided Risk Perception and Prognosis Prediction in the Whole Process of Laparoscopic Hepatobiliary and Pancreatic Surgery | enrolling by invitation | — | 1,500 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06028412 | Comparison of Sublobar and Lobectomy in Small (2 Cm or Less 0.5<CTR<1) Non-small Cell Lung Cancer: a Prospective, Multicenter Randomized Controlled Study | enrolling by invitation | N/A | 660 | Xiaolong Yan, Dr.OTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04195503 | Liver Transplant for Stable, Advanced Intrahepatic Cholangiocarcinoma | enrolling by invitation | N/A | 10 | University Health Network, TorontoOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05877456 | Validation of the Global Polypectomy Assessment Tool (GPAT)(GPAT) | enrolling by invitation | — | 100 | University Hospital, GhentOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT06283576 | Pancreatic Cancer Initial Detection Via Liquid Biopsy(PANCAID) | enrolling by invitation | — | 200 | Karolinska University HospitalOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT04793633 | Evaluating LINFU™: A Noninvasive Method for Collecting Pancreatic Cells for the Early Detection of Pancreatic Cancer | enrolling by invitation | — | 500 | Adenocyte, LLCINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06303583 | Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma(CRIS) | enrolling by invitation | Phase 1 / Phase 2 | 30 | Qiu GuoqinOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06076252 | Modified vs Conventional Blumgart Anastomosis of LPD for the Effects of Pancreatic Fistula of Periampullary Carcinoma | enrolling by invitation | N/A | 150 | Affiliated Hospital of Guangdong Medical UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT03713229 | Seville Cohort of People Living With HIV at Risk for Anal Cancer(SeVIHanal) | enrolling by invitation | — | 3,000 | Hospitales Universitarios Virgen del RocíoOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT06048926 | Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma | enrolling by invitation | N/A | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01511393 | An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC) | enrolling by invitation | — | 6,750 | Novo Nordisk A/SINDUSTRY | 1 | Jun 13, 2023 | clinicaltrials |
| NCT05740111 | The PREPAIRD Study: Personalized Surveillance for Early Detection of Pancreatic Cancer in High Risk Individuals(PREPAIRD) | enrolling by invitation | N/A | 200 | Oslo University HospitalOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT05171335 | Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients | enrolling by invitation | Phase 2 | 50 | The Methodist Hospital Research InstituteOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT04762459 | Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection(APEX) | enrolling by invitation | Phase 3 | 606 | Chinese Academy of Medical SciencesOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT04466189 | Prospective Cohort Study of Pancreatic Cancer Patients Treated With Proton Beam Therapy | enrolling by invitation | — | 120 | National Cancer Center, KoreaOTHER_GOV | 1 | Jul 13, 2020 | clinicaltrials |
| NCT03474237 | A Prospective Cohort Study for Patients With Adrenal Diseases | enrolling by invitation | — | 1,500 | Seoul National University HospitalOTHER | 1 | Mar 18, 2020 | clinicaltrials |
Data updated 22 days agoSource updated May 11, 2025source: clinicaltrials